What is JUNS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for JUNS?

P/E (TTM) is n/a and 52-week range is $2.05 to $110.62 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s JUNS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for JUNS?

The company profile lists revenue (TTM) near $153K, net income (TTM) near -$1.64B, EPS (TTM) near -$18.57 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Jupiter Neurosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Palm Beach Gardens, Florida, US, 1.3M shares outstanding, ISIN US48208B3024 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Jupiter Neurosciences Inc

$JUNS

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 5 full-time employees. The company went IPO on 2024-12-03. The firm is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The firm's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The firm's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. The company is also focused on a Phase IIa clinical study in Parkinson's disease. The company also has rights in ALA-002.

Employees

Website

jupiterneurosciences.com/

IPO

2024-12-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US48208B3024

Headquarters

Palm Beach Gardens, Florida, US

Shares outstanding

1.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

2.25%

Browse other companiesFree AI scores and summaries for more stocks